Graybug Vision Inc (GRAY)

NASDAQ
4.170
+0.180(+4.51%)
After Hours
4.240
+0.070(+1.679%)
- Real-time Data
  • Volume:
    799,861
  • Bid/Ask:
    4.130/4.240
  • Day's Range:
    3.967 - 4.280

GRAY Overview

Prev. Close
3.99
Day's Range
3.967-4.28
Revenue
-
Open
4
52 wk Range
3.43-37.88
EPS
-
Volume
799,861
Market Cap
87.8M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,214,753
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
21,055,944
Next Earnings Date
31 Aug 2021
What is your sentiment on Graybug Vision Inc?
or
Market is currently closed. Voting is open during market hours.

Graybug Vision Inc News

Graybug Vision Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellSell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong SellSell
SummaryNeutralStrong BuyStrong BuyStrong SellSell

Graybug Vision Inc Company Profile

Graybug Vision Inc Company Profile

Employees
32

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company’s lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.